News | Quality Assurance (QA) | October 26, 2018

Sun Nuclear Surpasses 100 Units Shipped Milestone With SRS MapCheck

Latest version of quality assurance device for stereotactic radiosurgery integrates SNC Patient v8.1 to provide absolute dose

Sun Nuclear Surpasses 100 Units Shipped Milestone With SRS MapCheck

October 26, 2018 — Sun Nuclear Corp. announced the 100th shipment of its new SRS MapCheck for stereotactic radiosurgery (SRS). The milestone device will be used at a new Kaiser Permanente facility in California to help with commissioning of their stereotactic program, including end-to-end testing and dosimetric validations.

Released in May 2018, the SRS MapCheck has generated significant clinical interest from radiation therapy clinics worldwide, according to Sun Nuclear. With the recent release of its latest integrated software, SNC Patient v8.1, the SRS MapCheck provides absolute dose.

The SRS MapCheck is a stereotactic patient quality assurance (QA) tool that replaces film for patient-specific stereotactic QA. It was designed to insert into Sun Nuclear’s StereoPhan phantom for stereotactic commissioning and end-to-end testing. Together, these tools expedite the workflow for time-sensitive patient QA.

“The SRS MapCHECK shows very good agreement with film dosimetry for field sizes ranging from 7.0 cm to 0.5 cm,” noted Brett Miller, MS, DABR, University of Tennessee Medical Center, an early adopter of SRS MapCheck. “It proves to be an effective, time-saving substitute for film and point dose measurements.”

SNC Patient software compares the dose distribution of the treatment plan file imported from a treatment planning system (TPS) to the actual measured values. The release of v8.1 adds the Absolute Dose feature. With this release, users can query various points from the dose distribution, including absolute dose from the measured and planned dose data, absolute and relative dose difference between measured and planned dose data, and location relative to isocenter. Measurements use standard radiotherapy dose comparison metrics: gamma analysis, dose difference analysis and supports sub-millimeter distance criterion.

SRS MapCheck was on display at the 2018 American Society for Radiation Oncology (ASTRO) annual meeting, Oct. 21-24 in San Antonio, Texas.

For more information: www.sunnuclear.com

Related Content

New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing  synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of  the anatomy.

A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of the anatomy.

Feature | Radiation Oncology | May 29, 2019 | By Jeff Zagoudis
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin
Sponsored Content | Case Study | Radiation Therapy | May 29, 2019
The so-called “Grey Tsunami” of baby boomers using healthcare services isn’t taking the Radiation Medicine Program at